Home › Castration-Resistant Prostatic Cancer › Ohio
Castration-Resistant Prostatic Cancer clinical trials in Ohio
4 studies for Castration-Resistant Prostatic Cancer are looking for participants at sites in Ohio.
Cities in Ohio
A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- University of Cincinnati, Cincinnati
- University Hospital of Cleveland, Cleveland
RecruitingPhase 3
Ages 18 and older · Men · Updated Sep 25, 2026 · NCT07164443A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- University of Cincinnati, Cincinnati
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07225946Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)
- University Hospitals Cleveland Medical Center ( Site 0043), Cleveland
RecruitingPhase 1/2
Ages 18 and older · All sexes · Updated Sep 17, 2026 · NCT06353386Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
- University of Cincinnati Medical Center, Cincinnati
- The Ohio State University, Columbus
RecruitingPhase 1
Ages 18 to 100 · Men · Updated Aug 13, 2026 · NCT05519449From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.